1. Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124–35.
2. Janssen Pharmaceuticals. Janssen announces Health Canada approval of CABENUVA™, the first long-acting regimen for the treatment of HIV [media release]. 20 Mar 2020.
https://www.janssen.com
.
3. ViiV Healthcare. ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy [media release]. 3 Nov 2015.
https://www.viivhealthcare.com
.
4. Tibotec Pharmaceuticals. EDURANT® (Rilpivirine) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in treatment-naïve adults with HIV-1 [media release]. 23 Sep 2011.
https://www.jnj.com/
.
5. Janssen Pharmaceuticals. Complete response letter issued from U.S. FDA for investigational long-Acting HIV regimen [media release]. 21 Dec 2019.
https://www.janssen.com
.